$7.20
0.07% today
Nasdaq, Aug 12, 04:49 pm CET
ISIN
US98422L1070
Symbol
XERS

Xeris Pharmaceuticals Inc Stock price

$7.20
+2.09 40.90% 1M
+3.64 102.25% 6M
+3.81 112.39% YTD
+4.95 220.00% 1Y
+5.38 295.60% 3Y
+3.91 118.85% 5Y
-13.02 64.39% 10Y
-13.02 64.39% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.36 5.26%
ISIN
US98422L1070
Symbol
XERS
Industry

Key metrics

Basic
Market capitalization
$861.6m
Enterprise Value
$1.0b
Net debt
$171.3m
Cash
$58.4m
Shares outstanding
156.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.9 | 3.1
EV/Sales
4.6 | 3.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.2%
Return on Equity
185.2%
ROCE
-10.2%
ROIC
-8.5%
Debt/Equity
-6.5
Financials (TTM | estimate)
Revenue
$222.6m | $274.8m
EBITDA
$-11.7m | $35.0m
EBIT
$-22.5m | $11.0m
Net Income
$-45.1m | $-14.0m
Free Cash Flow
$-27.4m
Growth (TTM | estimate)
Revenue
29.9% | 35.3%
EBITDA
65.9% | 253.7%
EBIT
50.0% | 132.7%
Net Income
30.0% | 74.5%
Free Cash Flow
36.8%
Margin (TTM | estimate)
Gross
82.2%
EBITDA
-5.2% | 12.8%
EBIT
-10.1%
Net
-20.3% | -5.1%
Free Cash Flow
-12.3%
More
EPS
$-0.3
FCF per Share
$-0.2
Short interest
12.7%
Employees
377
Rev per Employee
$540.0k
Show more

Is Xeris Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Xeris Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

Buy
83%
Hold
17%

Financial data from Xeris Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
223 223
30% 30%
100%
- Direct Costs 40 40
35% 35%
18%
183 183
29% 29%
82%
- Selling and Administrative Expenses 169 169
12% 12%
76%
- Research and Development Expense 25 25
1% 1%
11%
-12 -12
66% 66%
-5%
- Depreciation and Amortization 11 11
0% 0%
5%
EBIT (Operating Income) EBIT -22 -22
50% 50%
-10%
Net Profit -45 -45
30% 30%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Xeris Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xeris Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
5 days ago
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John P. Shannon - CEO & Director Steven M.
Positive
The Motley Fool
5 days ago
Xeris (XERS) Q2 Revenue Jumps 49%
Neutral
Business Wire
5 days ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. “Total revenue in the second quarter increased ...
More Xeris Pharmaceuticals Inc News

Company Profile

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.

Head office United States
CEO John Shannon
Employees 377
Founded 2005
Website www.xerispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today